Robert E. Waltermire is VP at MADRIGAL PHARMACEUTICALS, INC. (MDGL). They have made 10 open-market trades across 1 company since 2023, most recently 2025-03-05.
CIK 0001876996
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MDGL | 10,918 | $4.4M |
Shares reported on the most recent Form 4, priced at the 2025-03-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MDGL | SELL | 2025-03-05 | 2025-03-07 | $341.56 | $9.2M | +5.5% | -3.9% | -15.1% |
| MDGL | SELL | 2025-02-28 | 2025-03-04 | $341.07 | $837K | +7.5% | +1.0% | -15.8% |
| MDGL | SELL | 2025-01-24 | 2025-01-27 | $335.24 | $35K | +4.1% | +12.1% | +4.4% |
| MDGL | SELL | 2025-01-17 | 2025-01-17 | $273.41 | $242K | +15.4% | +15.9% | +2.9% |
| MDGL | SELL | 2024-06-14 | 2024-06-18 | $280.00 | $532K | +2.2% | +2.1% | -14.6% |
| MDGL | SELL | 2024-06-12 | 2024-06-14 | $285.00 | $570K | +3.6% | +1.5% | -14.9% |
| MDGL | SELL | 2024-05-21 | 2024-05-23 | $231.34 | $479K | +0.5% | +20.9% | +9.1% |
| MDGL | SELL | 2023-12-14 | 2023-12-18 | $235.50 | $942K | -0.6% | +3.1% | +21.7% |
| MDGL | SELL | 2023-12-12 | 2023-12-14 | $222.82 | $847K | +0.1% | +3.1% | +15.4% |
| MDGL | SELL | 2023-02-28 | 2023-03-02 | $273.47 | $4.3M | -9.1% | -7.6% | +3.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.